



**Australian Government**  
**Department of Health**  
**Therapeutic Goods Administration**

## Public Summary

<b>Summary for ARTG Entry:</b>	94753	Super Calcium Plus with Boron
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Herbs of Gold Pty Ltd	
<b>Postal Address</b>	PO Box 3143, KIRRAWEE, NSW, 2232 Australia	
<b>ARTG Start Date</b>	10/06/2003	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Super Calcium Plus with Boron

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	28/05/2020
---------------------	-------------------------	-----------------------	------------

#### Permitted Indications

Maintain/support general health and wellbeing  
Maintain/support healthy teeth  
Maintain/support teeth mineralisation  
Maintain/support bone health  
Maintain/support bone health in post-menopausal women  
Maintain/support bone mass/density/integrity  
Maintain/support bone mass/density/integrity in post-menopausal women  
Maintain/support bone strength  
Maintain/support bone strength in post-menopausal women  
Help maintain/support bone mineralisation  
A diet deficient in calcium can lead to osteoporosis in later life. Calcium may help prevent osteoporosis when dietary intake is inadequate  
Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life  
Maintain/support cardiovascular system health  
Maintain/support healthy cardiovascular system function  
Maintain/support healthy muscle contraction function  
Maintain/support muscle health  
Maintain/support muscle function  
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)  
Maintain/support nervous system health  
Maintain/support nervous system function

#### Indication Requirements

Product presentation must not imply or refer to serious cardiovascular conditions.

Public Summary



**Australian Government**  
**Department of Health**  
**Therapeutic Goods Administration**

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Indication can only be used for medicines that contain calcium as an active ingredient and the recommended daily dose of the medicine must provide at least 290 milligrams of elemental calcium.

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

Not to be taken by children under 2 years old (or words to that effect).

Adults only.

#### Additional Product information

#### Pack Size/Poison information

##### Pack Size

##### Poison Schedule

#### Components

##### 1 . Formulation 1

**Dosage Form** Tablet, film coated

**Route of Administration** Oral

##### Visual Identification

##### Active Ingredients

<b>borax</b>	<b>8.82 mg</b>
Equivalent: boron	1 mg
<b>calcium citrate tetrahydrate</b>	<b>1.126 g</b>
Equivalent: calcium	237.3 mg
<b>colecalfiferol</b>	<b>.0025 mg</b>
<b>Equisetum arvense herb Extract dry concentrate</b>	<b>10 mg</b>
Equivalent: Equisetum arvense (Dry)	50 mg
<b>hydroxyapatite</b>	<b>162.5 mg</b>
Equivalent: calcium	39 mg
<b>magnesium oxide</b>	<b>207.3 mg</b>
Equivalent: magnesium	125 mg
<b>manganese amino acid chelate</b>	<b>15 mg</b>
Equivalent: manganese	1.5 mg
<b>phytomenadione</b>	<b>2.5 microgram</b>
<b>zinc gluconate</b>	<b>2.3 mg</b>
Equivalent: zinc	300 microgram

##### Other Ingredients (Excipients)

Acacia  
Carnauba Wax  
croscarmellose sodium  
crospovidone  
dl-alpha-tocopherol  
hydrogenated soya oil

# Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

hydrogenated vegetable oil  
hydrolysed gelatin  
hypromellose  
macrogol 400  
magnesium stearate  
maize starch  
povidone  
silicon dioxide  
stearic acid  
sucrose  
titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary